Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

cemiplimab

- PMLiVE

UK scientists discover two genes offering potential drug targets against skin cancer

The three major types of skin cancer are basal cell carcinoma, squamous cell carcinoma and melanoma

- PMLiVE

Sanofi presents promising results for investigational frexalimab in relapsing forms of MS

Approximately 85% of patients are initially diagnosed with relapsing forms of the neurological disease

- PMLiVE

Sanofi announces UK launch of inactivated rabies vaccine Verorab for all age groups

The rare neurotrophic virus is responsible for an estimated 59,000 global deaths every year

- PMLiVE

Co-funded trial shows promise for Sanofi’s diabetes drug in early Parkinson’s disease

According to WHO, the neurodegenerative disease affected more than 8.5 million people worldwide in 2019

- PMLiVE

Merck’s Keytruda regimen granted EC approval for expanded lung cancer use

The approval represents the sixth lung cancer indication for the anti-PD-1 therapy in Europe

- PMLiVE

Sanofi and Owkin expand AI collaboration to include drug positioning in immunology

The expansion builds on the companies’ strategic alliance previously announced in 2021

- PMLiVE

Merck presents positive phase 3 data for Keytruda plus CRT in advanced cervical cancer

According to WHO, cervical cancer is the fourth most common cancer in women globally

- PMLiVE

Sanofi shares promising results for amlitelimab in moderate-to-severe atopic dermatitis

Amlitelimab could potentially offer treatment for a range of other immune-mediated diseases and inflammatory disorders

- PMLiVE

Sanofi’s Xenpozyme not recommended by NICE for ultra-rare disease ASMD

An estimated 40 to 50 people in England are living with the lysosomal storage disorder

- PMLiVE

Sanofi’s Rezurock fast-tracked by NHS for rare chronic graft versus host disease

Around 400 stem cell or bone marrow transplant patients will develop the condition each year in England

- PMLiVE

Sanofi presents positive results for rilzabrutinib in chronic spontaneous urticaria

Phase 3 development of the treatment is expected to commence later this year

- PMLiVE

Medicxi forms Alys Pharma with six dermatology-focused companies with $100m

Alys will keep its component companies separate to focus on their platforms

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links